Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 639-642 , May 2009

Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study

  • Carmen Martínez

      Affiliations

    • Institute of Hematology and Oncology, Hematology Department, Hematopoietic Transplantation Unit, Hospital Clinic, Barcelona, Spain
    • Corresponding Author InformationCorrespondence and reprint requests: Carmen Martínez, Institute of Hematology and Oncology, Hematology Department, Hematopoietic Transplantation Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain.
    • ,
  • Carlos Solano

      Affiliations

    • Hematology Department, Hospital Clínico, Valencia, Spain
    • ,
  • Christelle Ferrá

      Affiliations

    • Hematology Department, Hospital Germans Trias i Pujol, Barcelona, Spain
    • ,
  • Antonia Sampol

      Affiliations

    • Hematology Department, Hospital Son Dureta, Palma de Mallroca, Spain
    • ,
  • David Valcárcel

      Affiliations

    • Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • José Antonio Pérez-Simón

      Affiliations

    • Hematology Department, Hospital Clínico Universitario de Salmanca, Salamanca, Spain
    • ,
  • Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular)

Received 12 December 2008 ,Accepted 19 January 2009.

References 

  1. Bolanos-Meade J, Vogelsang GB. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol. 2005;12:40–44
  2. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119–4126
  3. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82:807–812
  4. Hale G. The CD52 antigen and development of the CAMPATH-1H antibodies. Cytotherapy. 2001;3:137–143
  5. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575–581
  6. Schomchik WD, Couzens MS, Tang CB, et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415
  7. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987–992
  8. Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105:2227–2234
  9. Collin MP, Munster D, Clark G, et al. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of graft-versus-host disease. Transplantation. 2005;79:722–725
  10. Shah AJ, Kapoor N, Crooks GM, et al. The effects of Campath-1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant. 2007;13:584–593
  11. von dem Borne PA, Beaumont F, Starrenburg CW, et al. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica. 2006;91:1559–1562
  12. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2002;96:2419–2425
  13. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukaemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107:1724–1730
  14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304
  15. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. New Engl J Med. 1975;292:895–902
  16. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–864
  17. Carella AM, Beltrami G, Scalzulli PR, et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant. 2004;33:131–132
  18. Wandroo F, Auguston B, Cook M, et al. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant. 2004;34:285–287
  19. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:10–15

 Financial disclosure: See Acknowledgments on page 642.

PII: S1083-8791(09)00057-3

doi: 10.1016/j.bbmt.2009.01.014

Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 639-642 , May 2009

Article Tools